SCHEMBL30698312

SCHEMBL30698312

COc1cc2ncc(-c3ccc(C#N)c(N[C@H]4CN(C(=O)OC(C)(C)C)C[C@@H]4F)n3)n2nc1C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKE Q14164 2/20 0.40
▸ TBK1 Q9UHD2 2/20 0.40
▸ NSD2 O96028 2/20 0.38
▸ GPR119 Q8TDV5 3/20 0.38
▸ PIK3CD O00329 1/20 0.37
▸ LRRK2 Q5S007 2/20 0.36
▸ EHMT2 Q96KQ7 1/20 0.36
▸ EGLN2 Q96KS0 2/20 0.35
▸ RIPK1 Q13546 1/20 0.34
▸ CFTR P13569 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CRHBP P24387 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CRHR2 Q13324 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24542620 0.85 FLT3 (0.40) CFTRKDM4EMEN1ALDH1A1HPGD
SCHEMBL30698336 0.83 SYK (0.38) IKBKETBK1NSD2PIK3CDEHMT2
SCHEMBL30698339 0.82 FLT3 (0.42) LRRK2NRASFLT3
SCHEMBL27327095 0.82 FLT3 (0.42) LRRK2NRASFLT3
SCHEMBL27331052 0.82 FLT3 (0.42) LRRK2NRASFLT3
SCHEMBL27327915 0.81 FLT3 (0.46) LRRK2NRASFLT3
SCHEMBL31739845 0.81 FLT3 (0.46) LRRK2NRASFLT3
SCHEMBL31639276 0.80 NSD2 (0.35) IKBKETBK1NSD2PIK3CDEHMT2
SCHEMBL31739791 0.80 LRRK2 (0.38) NSD2LRRK2EGLN2KDM4EALDH1A1
SCHEMBL31000243 0.79 CFTR (0.39) CFTRUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-12-04 — — US disclosed
EP-4540248-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Children's Hospital Medical Center (US) 2025-04-23 — — EP disclosed
WO-2023245123-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK2 IKBKE 16/4885TBK1 40/4885NSD2 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback